Connect Biopharma Holdings Limited Ordinary Shares (CNTB) Stock
Key stats
- Market cap
- $43.38M
- Price / Earnings ratio
- -0.6x
- EPS (TTM)
- -$1.19
- Volume
- Loading
- 52-week high
- $3.82
- 52-week low
- $0.68
Source: third-party data provider, as of November 13, 2026
Compare with CNTB
Recent news

Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
CNTB

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
CNTB

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
CNTB

Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
CNTB
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 28.98
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.01
- SMA 50
- $1.11
- Price below SMA 50
- EMA 50
- $1.11
- Price below EMA 50
- SMA 200
- $2.13
- Price below SMA 200
- EMA 200
- $1.91
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
CNTB

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
CNTB

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
CNTB

Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
CNTB
News tone: automated (AI) classification of the article's content, not a price prediction.
About Connect Biopharma Holdings Limited Ordinary Shares
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Barry David Quart Pharm.D. | CEO & Director | 1957 |
| Mr. David L. Szekeres J.D. | President | 1974 |
| Ms. Lisa Peraza CPA | Senior Vice President of Finance | 1977 |
| Mr. Jeff Cohn J.D. | General Counsel & Corporate Secretary | 1982 |
| Mr. Sean T. Ristine | Vice President of Human Resources | 1970 |
| Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC | 1964 |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) | — |
| Ms. Kimberly J. Manhard | Executive VP & Chief Development Officer | 1960 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 28.98
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.01
- SMA 50
- $1.11
- Price below SMA 50
- EMA 50
- $1.11
- Price below EMA 50
- SMA 200
- $2.13
- Price below SMA 200
- EMA 200
- $1.91
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $5.40
- High
- $7.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.4 | +11.7 | -53.4 | -18.4 | -11.5 |



